Active Monitoring Promising for Women with Low-Risk Ductal Carcinoma In Situ By Ogkologos - January 8, 2025 708 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COMET study Source RELATED ARTICLESMORE FROM AUTHOR Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less FDA Approves Acalabrutinib with Venetoclax for CLL or SLL No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC MOST POPULAR Beloved Jeopardy! Host Alex Trebek Has Passed Away After Battle with... November 9, 2020 A Combination of Trifluridine-Tipiracil Plus Bevacizumab Results in Longer Overall Survival... May 9, 2023 ESMO Highlights the Importance of Prioritising the Fight Against Cancer in... September 10, 2025 Cancer Research UK spin-out goes public, ready to invest more in... May 17, 2021 Load more HOT NEWS Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients... Patient Guide in Colorectal Cancer Now Available in Bulgarian What to Know About Kidney Cancer Genetic Conditions and Genetic Counseling Engaging People with Low-Grade Glioma in Cancer Research
